{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458779888
| ImageFile = Atevirdine structure.svg
| ImageSize = 220px
| IUPACName = [4-[3-(Ethylamino)pyridin-2-yl]piperazin-1-yl]-(5-methoxy-1''H''-indol-2-yl)methanone
| OtherNames =

| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N24015WC6D
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54835
| InChI = 1/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3
| InChIKey = UCPOMLWZWRTIAA-UHFFFAOYAK
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 136816-75-6
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H25N5O2/c1-3-22-18-5-4-8-23-20(18)25-9-11-26(12-10-25)21(27)19-14-15-13-16(28-2)6-7-17(15)24-19/h4-8,13-14,22,24H,3,9-12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UCPOMLWZWRTIAA-UHFFFAOYSA-N
| PubChem = 60848
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 280527
| SMILES = O=C(N2CCN(c1ncccc1NCC)CC2)c4cc3cc(OC)ccc3n4
}}

| Section2 = {{Chembox Properties
| Formula = C<sub>21</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>
| MolarMass = 379.46 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

|Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Ateviridine''' is [[non-nucleoside reverse transcriptase inhibitor]] that has been studied for the treatment of [[HIV]].<ref name="pmid10774589">{{cite journal |vauthors=Morse GD, Reichman RC, Fischl MA |title=Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams |journal=Antiviral Res. |volume=45 |issue=1 |pages=47â€“58 |date=January 2000 |pmid=10774589 |doi= 10.1016/S0166-3542(99)00073-X|url=http://linkinghub.elsevier.com/retrieve/pii/S016635429900073X|display-authors=etal}}</ref>

==Synthesis==
[[File:Atevirdine synthesis.png|thumb|center|500px|Atevirdine synthesis:<ref>D. L. Romero, Drugs Future 19, 9 (1995).</ref><ref>D. L. Romero et al., {{Cite patent|WO|9109849}} (1991 to [[Upjohn]]).</ref> [[Structure-activity relationship|SAR]]:<ref>{{Cite journal | doi = 10.1021/jm00033a018| pmid = 7512142| title = Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors| journal = Journal of Medicinal Chemistry| volume = 37| issue = 7| pages = 999| year = 1994| last1 = Romero | first1 = D. L. | last2 = Morge | first2 = R. A. | last3 = Biles | first3 = C. | last4 = Berrios-Pena | first4 = N. | last5 = May | first5 = P. D. | last6 = Palmer | first6 = J. R. | last7 = Johnson | first7 = P. D. | last8 = Smith | first8 = H. W. | last9 = Busso | first9 = M. | last10 = Et. Al.}}</ref>]]
Preparation of the pyridylpiperazine moiety starts by aromatic displacement of chlorine from 2-Chloro-3-nitropyridine by piperazine to give '''3'''. The secondary amine is then protected as its BOC derivative by reaction with [[Di-tert-butyl dicarbonate]] ([[Boc anhydride]]) to give '''4'''. The nitro group is then reduced by [[catalytic hydrogenation]]. Reductive alkylation with acetaldehyde in the presence of [[lithium cyanoborohydride]] gives the corresponding N-ethyl derivative. The [[protecting group]] is then removed by reaction with [[Trifluoroacetic acid|TFA]]. Reaaction of the resulting amine with the imidazolide derivative of 5-Methoxy-3-indoleacetic acid affords the amide reverse transcriptase inhibitor, atevirdine.

==See also==
*[[Delavirdine]]

==References==
{{reflist}}

{{Antiretroviral drug}}
{{Piperazines}}

[[Category:Abandoned drugs]]
[[Category:Carboxamides]]
[[Category:Indoles]]
[[Category:Non-nucleoside reverse transcriptase inhibitors]]
[[Category:Phenol ethers]]
[[Category:Piperazines]]
[[Category:Pyridines]]


{{Antiinfective-agent-stub}}